AU2177701A - Use of hmg-coa reductase inhibitors for treating seborrhea - Google Patents

Use of hmg-coa reductase inhibitors for treating seborrhea

Info

Publication number
AU2177701A
AU2177701A AU21777/01A AU2177701A AU2177701A AU 2177701 A AU2177701 A AU 2177701A AU 21777/01 A AU21777/01 A AU 21777/01A AU 2177701 A AU2177701 A AU 2177701A AU 2177701 A AU2177701 A AU 2177701A
Authority
AU
Australia
Prior art keywords
hmg
coa reductase
reductase inhibitors
treating seborrhea
seborrhea
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU21777/01A
Inventor
Lionel Breton
Maria Dalko
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LOreal SA
Original Assignee
LOreal SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LOreal SA filed Critical LOreal SA
Publication of AU2177701A publication Critical patent/AU2177701A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A61K8/365—Hydroxycarboxylic acids; Ketocarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/37—Esters of carboxylic acids
    • A61K8/375—Esters of carboxylic acids the alcohol moiety containing more than one hydroxy group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
    • A61K8/4913—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid
    • A61K8/492—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid having condensed rings, e.g. indol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
    • A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
    • A61K2800/782—Enzyme inhibitors; Enzyme antagonists
AU21777/01A 1999-11-29 2000-11-24 Use of hmg-coa reductase inhibitors for treating seborrhea Abandoned AU2177701A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9914998A FR2801508B1 (en) 1999-11-29 1999-11-29 USE OF HMG COA-REDUCTASE INHIBITORS FOR THE TREATMENT OF SEBORRHEA
FR9914998 1999-11-29
PCT/FR2000/003288 WO2001039770A1 (en) 1999-11-29 2000-11-24 USE OF HMG-CoA REDUCTASE INHIBITORS FOR TREATING SEBORRHEA

Publications (1)

Publication Number Publication Date
AU2177701A true AU2177701A (en) 2001-06-12

Family

ID=9552650

Family Applications (1)

Application Number Title Priority Date Filing Date
AU21777/01A Abandoned AU2177701A (en) 1999-11-29 2000-11-24 Use of hmg-coa reductase inhibitors for treating seborrhea

Country Status (3)

Country Link
AU (1) AU2177701A (en)
FR (1) FR2801508B1 (en)
WO (1) WO2001039770A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004026297A1 (en) * 2002-09-20 2004-04-01 Kowa Co., Ltd. Preparation for external use
FR2868309B1 (en) * 2004-04-02 2006-05-26 Oreal COSMETIC USE OF AT LEAST ONE HMG-COA-REDUCTASE INHIBITOR AS AN AGENT FOR PREVENTING AND / OR COMBATTING EXPRESSION WRINKLES
ES2385752T3 (en) 2006-04-26 2012-07-31 Rosemont Pharmaceuticals Ltd Oral Liquid Compositions

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5021451A (en) * 1988-11-14 1991-06-04 Hoffman-La Roche Inc. Method for inhibiting hyperproliferative diseases
JPH04193836A (en) * 1990-11-26 1992-07-13 Banyu Pharmaceut Co Ltd Antihyperlipemic agent
IL110943A (en) * 1994-09-13 1997-02-18 Univ Ramot Compositions comprising an inhibitor of cholesterol synthesis for the treatment of skin disorders
EP0738510A3 (en) * 1995-04-20 2005-12-21 L'oreal Use of a HMG-CoA reductase inhibitor as an anti-ageing agent and as an anti-acne agent. Composition comprising at least one HMG-CoA reductase inhibitor and at least one active substance with scaling properties.
WO1997026874A1 (en) * 1996-01-23 1997-07-31 Novartis Ag Use of fluvastatin derivatives in skin disease and topical compositions containing them

Also Published As

Publication number Publication date
WO2001039770A1 (en) 2001-06-07
FR2801508A1 (en) 2001-06-01
FR2801508B1 (en) 2003-11-14

Similar Documents

Publication Publication Date Title
HUP0103007A3 (en) New salts of hmg-coa reductase inhibitors and process for their preparation
IL134272A0 (en) Combinations of hmg-coa reductase inhibitors and nicotinic acid and methods for treating hyperlipidemia
PL359820A1 (en) Hmg-coa reductase inhibitors and method
PL362477A1 (en) Hmg-coa reductase inhibitors and their use as medicaments for the treatment of cholesterol related diseases
AU2002251266A1 (en) Inhibitors of akt activity
AU5041300A (en) Inhibitors of factor xa
AU5100599A (en) Egf-genistein for prevention of restenosis
AU4166400A (en) Alkenyl and alkynyl compounds as inhibitors of factor xa
AU5155500A (en) Inhibitors of factor xa
AU3368400A (en) Aerosol compositions of hmg-coa reductase inhibitors for inhibiting inflammationassociated with pulmonary disease
EP1176964B8 (en) Uses of et743 for treating cancer
AU5619400A (en) Statine-derived tetrapeptide inhibitors of beta-secretase
HUP0102997A2 (en) Process for obtaining hmg-coa reductase inhibitors of high purity
HUP0100820A3 (en) Process for the obtaining of hmg-coa reductase inhibitors of high purity
AU7761398A (en) Hmg-coa reductase inhibitor preparation process
AU4543699A (en) Multibinding inhibitors of hmg-coa reductase
AU3270301A (en) Combined pde3 and pde4 inhibitor therapy for the treatment of obesity
AU2252101A (en) New synthesis of SPLA2 inhibitors
AU2177701A (en) Use of hmg-coa reductase inhibitors for treating seborrhea
GB2371748B (en) HMG-COA reductase inhibitor extended release formulation
AU2116201A (en) A therapeutic mixture of hmg-coa reductase inhibitors
HUP0105145A3 (en) Process for producing hmg-coa reductase inhibitor
AU4021700A (en) Methods of use of beta1-integrin inhibitors
HUP0201597A2 (en) Antilipemic combunations comprising hmg-coa reductase inhibitors and carnitines
AU4985200A (en) Methods of treating hypertension

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase